Cure My Disease

Don't miss your cure!

 Log in / Sign up

New biologic XmAb657 enters first human tests for autoimmune conditions

NCT ID NCT07284797

Recruiting now Disease control Sponsor: Xencor, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times

Summary

This early-phase trial is testing a new biologic drug called XmAb657 in 60 people, including healthy volunteers and those with autoimmune diseases like scleroderma, Sjögren's disease, and idiopathic inflammatory myopathies. The main goal is to check safety and how the body handles the drug. Participants receive the drug as an injection under the skin.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
XmAb657 (a biologic drug given as an injection under the skin)
What this could lead to
If successful, this could lead to a new treatment option for certain autoimmune diseases like scleroderma and Sjögren's disease.
What could go wrong
This is a very early Phase 1 trial focused on safety, not effectiveness. It is small (60 people) and may not lead to a working treatment. Side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired idiopathic inflammatory myopathy autoimmune disease diffuse scleroderma idiopathic inflammatory myopathy muscle tissue disorder myositis disease Sjogren syndrome systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY IDIOPATHIC INFLAMMATORY MYOPATHIES SJÖGREN'S DISEASE SYSTEMIC SCLEROSIS

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Xencor Investigative Site

    RECRUITING

    Melbourne, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.